Starpharma Holdings Ltd
ASX:SPL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Starpharma Holdings Ltd
Starpharma Holdings Ltd
Cash Equivalents
Starpharma Holdings Ltd
Cash Equivalents Peer Comparison
MYX
NEU
BOT
PBP
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Starpharma Holdings Ltd
ASX:SPL
|
Cash Equivalents
AU$32.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash Equivalents
AU$17.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Cash Equivalents
AU$12.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
34%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash Equivalents
AU$25.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Starpharma Holdings Ltd's Cash Equivalents?
Cash Equivalents
32.1m
AUD
Based on the financial report for Dec 31, 2023, Starpharma Holdings Ltd's Cash Equivalents amounts to 32.1m AUD.
What is Starpharma Holdings Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
1%
Over the last year, the Cash Equivalents growth was -27%. The average annual Cash Equivalents growth rates for Starpharma Holdings Ltd have been -23% over the past three years , -6% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
